Novo Nordisk stock tumbled over the latest results for its experimental weight loss pill
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
Novo Nordisk sees mixed results for new CB1 weight-loss pill
Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to higher doses of its oral drug was "limited" in its latest trial results. Morning Brief's Seana Smith and Brad Smith report on what this story means for the company.
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster weight loss than Wegovy in early clinical trials, according to data presented Wednesday at the European Association for the Study of Diabetes.
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results from a rival Novo Nordisk (NVO) drug.
‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
The Weight Loss Hacks That Claim to Work Like Ozempic
Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Early trial shows success for daily weight loss pill: 3 things to know
The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...
Yahoo5d
Once-a-day weight loss pill shows promise in trial
A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% ...
Ozempic maker has developed a pill that can cause weight loss of up to 13% in three months
The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to ...
While brand-name weight loss drugs are in short supply, a market for alternatives thrives
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...